Press releases

August 28, 2017

BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson’s Disease

Collaboration to Focus on a Disease Target in Parkinson’s Disease With Berg’s Interrogative Biology® Technology BOSTON, Aug. 28, 2017 – BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today...

May 15, 2017

BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa, a Rare Genetic Tissue Disorder

Biopharmaceutical and Patient Advocacy Group Join Forces to Galvanize the Disease Community and Advance Treatment Research BOSTON, May 15, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced...

April 3, 2017

BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Multiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

BOSTON, April 3, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG’s leading product...

March 27, 2017

New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology

BOSTON, March 27, 2017— BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company’s Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote...

February 15, 2017

BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

BOSTON, Feb. 15, 2017 — BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for...

January 12, 2017

BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT

Leading Health Companies Combine Health IT Expertise to Advance Patient Health Outcomes BOSTON, Jan. 12, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement between BERG Analytics, a...

November 14, 2016

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting BERG Interrogative Biology® Platform Identifies Potential Contributor to LRRK2-mediated Cell Death in Parkinson’s Disease BOSTON, November 14, 2016 — BERG, a biopharmaceutical...

November 1, 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016 Leading players at the forefront of healthcare innovation will discuss how emerging technologies are...

August 17, 2016

BERG Strengthens Financial Leadership And Expands Board Of Directors

BOSTON, Aug. 17, 2016 /PRNewswire/ — BERG, a technology-based biopharmaceutical company uncovering health solutions through a data-driven, systems biological research approach, today announced an expansion of its Board of Directors, adding three new members who bring a...

June 5, 2016

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

BOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510...

April 27, 2016

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

BOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in...

April 18, 2016

BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting

BOSTON, April 18, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced five poster presentations showing new promising preclinical pancreatic cancer data, including new biomarkers for detection and...

February 23, 2016

BERG Appoints Michael A. Kiebish As Chief Precision Medicine Officer

New CPMO position spotlights growing importance of precision medicine in disease treatment Feb 23, 2016, 09:04 ET from BERG BOSTON, Feb. 23, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today...

February 9, 2016

BERG Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer

BERG Hires Bristol-Myers Squibb Former Head of Finance Feb 09, 2016, 09:02 ET from BERG BOSTON, Feb. 9, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, has announced the appointment of Jason...

September 30, 2015

Berg Joins U.K. Prime Minister’s Initiative, Genomics England to Sequence 100,000 Genomes

Boston based biotech company to apply its analytics platform to GENE Consortium data Sep 30, 2015, 10:23 ET from Berg BOSTON, Sept. 30, 2015 /PRNewswire/ — Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will...

September 8, 2015

National Institutes of Health to Evaluate Berg’s Drug for the Treatment of Kidney Cancer

BOSTON, Sept. 8, 2015 — Berg, a Boston-based biopharmaceutical company, has announced that it has entered into a Materials-Cooperative Research and Development Agreement (M-CRADA) with the United States National Institutes of Health (NIH) for the treatment of kidney...

June 1, 2015

Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy

Jun 01, 2015, 08:00 ET from Berg BOSTON, June 1, 2015 /PRNewswire/ — Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on...

May 12, 2014

BERG and Medical University of South Carolina Announce First of Its Kind Collaboration to Discover Lupus Biomarker

Research Partnership Will Combine Efforts of Leading Lupus Experts With BERG’s Award Winning Technology to Develop New, Targeted Therapies May 12, 2014, 10:00 ET from Berg FRAMINGHAM, Mass. and CHARLESTON, S.C., May 12, 2014 /PRNewswire/ — Berg and the Medical University of...

February 18, 2014

Berg And The Parkinson’s Institute And Clinical Center Announce Key Clinical Study Focused On Game-changing Innovations In Parkinson’s Disease Biomarker Discovery

Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets Feb 18, 2014, 09:15 ET from Berg FRAMINGHAM, Mass. and SUNNYVALE, Calif., Feb. 18, 2014 /PRNewswire/ — Berg and the Parkinson’s Institute and...

Showing 19 of 40 press releases - Page 2 of 2